Organon [OGN] vs Eli Lilly and [LLY] Detailed Stock Comparison

Organon & Co.

NYSE
Loading...

Eli Lilly and Company

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Organon & Co. wins in 6 metrics, Eli Lilly and Company wins in 15 metrics, with 0 ties. Eli Lilly and Company appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Organon & Co. Eli Lilly and Company Better
P/E Ratio (TTM) 11.94 40.09 Organon & Co.
Price-to-Book Ratio 2.98 31.01 Organon & Co.
Debt-to-Equity Ratio 1,170.21 165.31 Eli Lilly and Company
PEG Ratio -0.04 0.79 Eli Lilly and Company
EV/EBITDA 6.33 26.61 Organon & Co.
Profit Margin (TTM) 3.01% 31.67% Eli Lilly and Company
Operating Margin (TTM) 16.19% 44.90% Eli Lilly and Company
EBITDA Margin (TTM) 16.19% 44.90% Eli Lilly and Company
Return on Equity 30.56% 101.16% Eli Lilly and Company
Return on Assets (TTM) 6.22% 19.42% Eli Lilly and Company
Free Cash Flow (TTM) $384.00M $5.96B Eli Lilly and Company
Dividend Yield 1.10% 0.60% Organon & Co.
1-Year Return 44.69% 49.80% Eli Lilly and Company
Price-to-Sales Ratio (TTM) 0.36 12.63 Organon & Co.
Enterprise Value $10.46B $843.37B Eli Lilly and Company
EV/Revenue Ratio 1.68 12.94 Organon & Co.
Gross Profit Margin (TTM) 49.17% 82.52% Eli Lilly and Company
Revenue per Share (TTM) $24 $73 Eli Lilly and Company
Earnings per Share (Diluted) $0.72 $22.94 Eli Lilly and Company
Beta (Stock Volatility) 0.64 0.50 Eli Lilly and Company
Short % of Float 11.33% 0.97% Eli Lilly and Company

Organon & Co. vs Eli Lilly and Company Stock Performance Analysis

Loading Price Chart...

OGN
LLY

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Organon & Co.0.15%-0.15%0.98%86.23%78.77%84.94%
Eli Lilly and Company1.37%-0.01%9.99%4.58%1.77%-1.46%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Organon & Co.44.69%-32.49%-60.94%-59.88%-59.88%-59.88%
Eli Lilly and Company49.80%149.81%446.98%1,370.98%2,882.46%2,023.77%

Performance & Financial Health Analysis: Organon & Co. vs Eli Lilly and Company

MetricOGNLLY
Market Information
Market Cap i$2.24B$821.31B
Market Cap CategoryMid capMega cap
10 Day Avg. Volume i11,076,1682,387,476
90 Day Avg. Volume i6,348,9892,777,749
Last Close$13.40$1,078.78
52 Week Range$5.69 - $13.48$623.78 - $1,149.10
% from 52W High-0.59%-6.12%
All-Time High$39.47 (Feb 28, 2022)$1,149.10 (May 28, 2026)
% from All-Time High-66.05%-6.12%
Growth Metrics
Quarterly Revenue Growth-0.05%0.43%
Quarterly Earnings Growth-0.05%0.51%
Financial Health
Profit Margin (TTM) i0.03%0.32%
Operating Margin (TTM) i0.16%0.45%
Return on Equity (TTM) i0.31%1.01%
Debt to Equity (MRQ) i1,170.21165.31
Cash & Liquidity
Book Value per Share (MRQ)$2.89$29.66
Cash per Share (MRQ)$2.21$8.14
Operating Cash Flow (TTM) i$700.00M$16.81B
Levered Free Cash Flow (TTM) i$190.12M$1.95B
Dividends
Last 12-Month Dividend Yield i1.10%0.60%
Last 12-Month Dividend i$0.08$6.23

Valuation & Enterprise Metrics Analysis: Organon & Co. vs Eli Lilly and Company

MetricOGN (Apr 24, 2026)LLY (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i11.9440.09
Forward P/E i2.3321.82
PEG Ratio i-0.040.79
Price to Sales (TTM) i0.3612.63
Price to Book (MRQ) i2.9831.01
Market Capitalization
Market Capitalization i$2.24B$821.31B
Enterprise Value i$10.46B$843.37B
Enterprise Value Metrics
Enterprise to Revenue i1.6812.94
Enterprise to EBITDA i6.3326.61
Risk & Other Metrics
Beta i0.640.50
Book Value per Share (MRQ) i$2.89$29.66

Financial Statements Comparison: Organon & Co. vs Eli Lilly and Company

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricOGN (2025)LLY (2025)
Revenue/Sales i6.22B65.18B
Cost of Goods Sold i2.90B11.05B
COGS % of Revenue i46.7%17.0%
Gross Profit i3.31B54.13B
Gross Margin i53.3%83.0%
Research & Development i366.00M13.34B
Operating Income (EBIT) i1.23B29.70B
Operating Margin i19.7%45.6%
EBITDA i1.71B35.09B
EBITDA Margin i27.4%53.8%
Pre-Tax Income i425.00M25.73B
Pre-Tax Income % of Revenue i6.8%39.5%
Income Tax i238.00M5.09B
Income Tax % of Revenue i3.8%7.8%
Net Income (Profit) i187.00M20.64B
Profit Margin i3.0%31.7%

Balance Sheet & Liquidity Metrics

MetricOGN (2025)LLY (2025)
Cash & Equivalents i574.00M7.27B
Total Current Assets i4.35B55.63B
Total Current Assets % of Revenue i70.0%85.3%
Total Current Liabilities i2.39B35.23B
Total Current Liabilities % of Revenue i38.4%54.0%
Long-Term Debt i8.63B40.87B
Long-Term Debt % of Revenue i138.8%62.7%
Total Shareholders Equity i752.00M26.54B
Retained Earnings i1.11B24.47B
Retained Earnings % of Revenue i17.8%37.5%
Property, Plant & Equipment i013.49B

Cash Flow Statement Comparison

MetricOGN (2025)LLY (2025)
Operating Cash Flow i687.00M23.60B
Operating Cash Flow % of Revenue i11.1%36.2%
Capital Expenditures i1.00M-7.84B
Free Cash Flow i384.00M5.96B
FCF Margin i6.2%9.2%
Debt Repayment i-1.51B-778.00M
Common Stock Repurchase iN/A-4.11B

Short Interest & Institutional Ownership Analysis

MetricOGNLLY
Shares Short i22.13M7.70M
Short Ratio i6.502.73
Short % of Float i11.33%0.97%
Shares Outstanding i260.32M894.80M
Float Shares i258.71M890.99M
% Held by Insiders i0.33%0.17%
% Held by Institutions i77.57%84.77%
% Held by Public i22.10%15.06%

Dividend Analysis & Yield Comparison: Organon & Co. vs Eli Lilly and Company

MetricOGNLLY
Last 12-Month Dividend i$0.08$6.23
Last 12-Month Dividend Yield i1.10%0.60%
3-Year Avg Annual Dividend i$0.77$5.44
3-Year Avg Dividend Yield i1.16%0.18%
3-Year Total Dividends i$2.32$16.32
Ex-Dividend DateFeb 23, 2026Feb 13, 2026